Iovance Biotherapeutics Inc 2LB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- €11.42
- Day Range
- €11.78–13.24
- 52-Week Range
- —–—
- Bid/Ask
- €0.00 / €0.00
- Shares Outstanding
- 452.97M
- Market Cap
- $6.00B
- Volume/Avg
- 100 / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 19.50
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 975
- Website
- https://www.iovance.com
Valuation
|
Metric
|
2LB
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 9.30 |
Price/Sales | 19.50 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
2LB
|
|---|---|
Quick Ratio | 0.00 |
Current Ratio | 4.35 |
Interest Coverage | — |
Quick Ratio
2LB
Profitability
|
Metric
|
2LB
|
|---|---|
Return on Assets (Normalized) | −26.07% |
Return on Equity (Normalized) | −33.47% |
Return on Invested Capital (Normalized) | −32.65% |
Return on Assets
2LB
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|Mgs@Jd | LOCK|cK>^ | $129B | |||
| Moderna Inc
MRNA
| LOCK|%K!>J> | LOCK|@cF | $90B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|@&P%&r | LOCK|s?Lf> | $77B | |||
| argenx SE ADR
ARGX
| LOCK|&RSP@# | LOCK|Mb^ | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|P$&S?% | LOCK|k@ | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|%vDkJGW | LOCK|SlR$R | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|@K@K&!# | LOCK|NRsSw | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|^@MrG% | LOCK|s>K | $24B | |||
| Incyte Corp
INCY
| LOCK|Lq@FTt# | LOCK|$K | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|<CGB<? | LOCK|$h | $14B |
United States